Similarly, Rui et al. [32] confirmed the involvement of IL-22 and its receptor IL-22R1 in breast cancer progression, reporting elevated serum IL-22 levels and an increased IHC expression of IL-22 and IL-22R1 in tumour tissues compared to normal tissues [32]. This evidence concerns the gene IL22 and breast carcinoma.